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Abstract We have noted previously that growth of C6 glioma 
cells from low cell density to confluency and quiescence in serum 
is accompanied by changes in protein content of different protein 
kinase C (PKC) subspecies. Here we show that the same occurs 
as non-contact-inhibiting Swiss 3T6 fibroblasts grow to high 
density in the presence of serum. Protein expression of PKC 
subspecies a and 0 increases as the cells increase in density while 
that of PKC-r,; remains the same. Unusally, protein expression of 
PKC-E is completely down-regulated as cells grow beyond about 
50% confluency and no PKC-E protein can be detected in 3T6 
fibroblasts at high density by Western blotting. However, mRNA 
for PKC-E is expressed at all stages of fibroblast growth as 
revealed by RT -PCR. When high-density 3T6 fibroblasts are 
passaged to low density in fresh medium, re-expression of PKC-E 
protein is observed within 15 min and becomes down-regulated 
again as cells become more dense. This very rapid synthesis of 
PKC-E is not blocked by the transcription inhibitor actinomycin 
D but is inhibited by cycloheximide. PKC-E has some 
characteristics of a novel 'early response' protein whose synthesis 
in newly passaged 3T6 cells is regulated at the translational level. 
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1. Introduction 
Twelve subspecies have been defined to date in the protein 
kinase C (PKC) family of phospholipid-dependent serine! 
threonine kinases [1-3] but the role of individual PKC sub-
species in transducing the mitogenic effect of some hormones 
and growth factors is not fully characterised. PKC-r,; may be 
critical for mitogenic signal transduction since it can activate 
MAP kinase kinase [4] and can also induce phosphorylation 
and inactivation of IKB-a leading to an up-regulation of tran-
scription [5]. PKC-a can activate Raf-l by direct phosphoryl-
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ation leading to the activation of proliferation-associated 
genes via the MAP kinase cascade [6]. Over-expression experi-
ments show that conventional and novel group PKC subspe-
cies have contrasting effects on cell growth and cell morphol-
ogy [7,8]. The activity of cyclin-dependent kinases regulating 
the cell cycle in endothelial cells is influenced by down-regula-
tion-sensitive PKC subspecies such as a, ~, 0 and e [9]. PKC-
~II may regulate cell division through phosphorylation of la-
mins [10]. 
We have found [11] that the specific activity of PKC in-
creases as C6 glioma cells grow from low seeding density 
through several cell cycles to confluency and quiescence in 
the presence of serum. This increase in PKC activity is mainly 
due to a 3-4-fold increase in protein expression of the a and 0 
subspecies. At the same time protein expression of the 'Y and e 
subspecies is down-regulated while that of PKC-r,; does not 
alter. We find that such changes, especially of the a and 0 
subspecies of PKC, occur in a range of cells including L929 
fibroblasts and primary astrocytes and seem to be a common 
feature of cells growing to confluency. Here we show that the 
same changes occur as overgrowing 3T6 fibroblasts increase 
from low seeding density to high density in the presence of 
serum and that, most notably, protein expression of PKC-e is 
completely down-regulated as the cells increase in density even 
though message for this subspecies is still expressed. Further, 
resynthesis of PKC-e protein occurs rapidly when high-density 
3T6 cells are passaged. We suggest that PKC-e is a novel form 
of 'early response' protein perhaps required in newly passaged 
cells for adherence and cell spreading. 
2. Materials and methods 
2.1. Materials 
Swiss 3T6 fibroblasts were obtained from the European Collection 
of Animal Cell Cultures (Porton Down, UK). Cell culture plastic was 
from Corning (Bibby-Sterilin, Stone, Staff., UK). DMEM was from 
BioWhittaker (Wokingham, Berks., UK) or Life Technologies (Pais-
ley, Scotland). Foetal calf serum was from Sigma (Poole, Dorset, 
UK). Nitrocellulose blotting membrane (0.2 11m) was from Schelicher 
and Schuell (Anderman, London, UK) or Amersham (Little Chalfont, 
Bucks., UK). BCA and Coomassie protein detection kits were from 
Pierce (Life Science Labs., Luton, UK) as was the Supersignal che-
miluminescence detection system for detecting peroxidase-conjugated 
second antibodies on blots. Peroxidase-conjugated second antibodies 
for Western blotting were from Sigma. Dried milk powder, Marvel, 
was from KwikSave, York, UK. The Trizol RNA extraction kit and 
M-MLV reverse transcriptase were from Gibco (Paisley, Scotland). 
Hi-Strength LMP agarose and Hi-Pure agarose were from Biogene 
Ltd. (Bolnhurst, Beds., UK). Restriction enzymes were from New 
England Biolabs (Hitchen, UK). Taq polymerase was from Promega 
(Southampton, UK). Oligolabelling kit and the oligo dT(l2-18) and 
dNTPs were from Pharmacia (St. Albans, UK). [32yP]ATP was from 
NEN-DuPont (Stevenage, UK). 
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2.2. Cell Culture and cell sample preparation 
3T6 cells were grown in DMEM supplemented with 10% foetal 
bovine serum (DMEM/IO% FBS) in 25 or 75 cm2 flasks. Medium 
was changed every 2 days. The cells were passaged 1:4 when just 
confluent by rinsing twice with Tris/saline and then releasing cells 
with trypsin/EDTA (Gibco BRL) stopping the reaction with fresh 
DMEMIlO% FBS. Cells at different growth densities were taken for 
experimentation by rinsing twice with cold Tris/saline followed by 
either extraction with Trizol reagent to recover total RNA or scraping 
cells in 0.5 ml homogenisation buffer (HB, 50 mM Tris-HCI, pH 7.5, 
0.5 mM EDTA, 2 mM EGTA, 10 Ilg/ml aprotinin, 10 Ilg/mlleupep-
tin, 2 mM PMSF). Cells in HB were then homogenised, aliquots taken 
for protein assay by the BCA method (Pierce) and the remainder 
solubilised with 10% SDS and sample buffer in a 2: 1: 1, v/v ratio 
followed by boiling for 5 min. 
2.3. Western blotting 
Samples of cell homogenates equivalent to 30 Ilg protein, plus rat 
brain control samples and suitable markers, were resolved by SDS-
PAGE on 15% gels at a constant 120 V in a Bio-Rad minigel system 
[11]. Proteins were electrophoretically transfered to nitrocellulose 
membrane in 25 mM Tris base, 180 mM glycine containing 10% 
methanol (v/v) for 75 min at a constant current of 250 rnA. Subse-
quent Western blotting with Supersignal chemiluminescence detection 
was under standard conditions as we have described [11). Polyclonal 
antisera to the C-terminal peptide sequences of rat PKC subspecies 
were raised and characterised as described previously [11,12). Antisera 
were used at a dilution of 1 :2000. Detection of second antibody by 
chemiluminescence was on X-ograph blue X-ray film (X-O-graph, 
Malmsbury, Wilts., UK). In some experiments developed bands on 
films were scanned using a laser densitometer. 
2.4. RT-PCR reaction details 
Total RNA recovered using the Trizol extraction system was quan-
titated by measuring absorbance at 260 nm and was analysed for 
purity by electrophoresis on I % formaldehyde gels and by measure-
ment of the 260/280 nm ratio. The sequences of the 5' and 3' primers 
used for RT-PCR for PKC-li, PKC-£ were as we have described pre-
viously [13) but for PKC-~ the upstream primer was 5'-CTCACA-
GATGGAGCTGGAGG and the downstream primer was 3'-
GGTTCTCGGAGGTCATCTAC. First-strand cDNA was generated 
as follows: 5 Ilg total RNA (in 10 III ddH20) were heated to 70°C for 
5 min, placed on ice for 10 min and then added to a reverse-tran-
scriptase reaction mix. This contained I Ilg oligo dT(12-18), 50 mM 
Tris-HCI (PH 8.3), 75 mM KCI, 3 mM MgCh, 500 11M each dNTP, 
10 mM DTT, 1 U/IlI RNAse Inhibitor (Promega) and 200 U of M-
ML V Reverse Transcriptase (200 U/IlI, Gibco-BRL) in a final volume 
of 25 Ill. Reactions were incubated at 37°C for 60 min, then heated to 
100°C for 5 min to denature the enzyme and placed on ice. 
First-strand cDNA (2.5 Ill) was added to a PCR reaction containing 
50 mM KCI, 10 mM Tris-HCI (pH 9.0), 0.1% Triton X-IOO, 40 pmol 
each of appropriate 5' and 3' primers, 200 11M each dNTP, 1.5 mM 
MgCh and 0.5 U Taq DNA polymerase in a final volume of 40 Ill. 
Samples were subjected to an initial denaturation step at 94°C for 4 
min, then 30 subsequent cycles of 94°C/I min, 64°CIl min and 72°CI 
35 s, followed by a final extension at 72°C/2 min. PCR products were 
resolved by electrophoresis on a 1.5% agaroselTBE gel and visualised 
by ethidium bromide staining and UV illumination. Capillary transfer 
of PCR products to nylon membranes was performed as described by 
Sambrook et al. [14). DNA probes were labelled with [32a:P)dCTP 
using a Pharmacia oligo-labelling kit according to manufacturer's in-
structions. 
3. Results 
3.1. PKC subspecies protein expression in 3T3 and 3T6 cells 
The Swiss 3T6 cell line, derived from mouse embryos, has a 
fibroblast morphology. Unlike contact-inhibiting Swiss 3T3 
cells, 3T6 fibroblasts lack this property and overgrow. At 
various stages of growth to high density we found that 3T6 
cells express PKC subspecies a, 131, 0, e, I;. and ~ as revealed by 
Western blotting using our polyclonal anti-PKC subspecies-
specific antisera [11]. Expression of the I3n, y, e, t and 11 sub-
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Fig. I. Western blot analysis of (A) PKC-a:, (B) PKC-Ii and (C) 
PKC-~ protein expression in 3T6 fibroblasts at different stages of 
growth to high cell density. A (lanes 1-4): cells at 30-40%, 75%, 
100% density and overgrowing, respectively. B (lanes 1-4): cells at 
30-40%, 75%, 100% density and overgrowing, respectively. C: As 
for (B). In all cases 30 Ilg total cell protein was resolved by SDS-
PAGE on 15% gels and blotted under standard conditions as de-
scribed. Markers are 89 and 77 kDa. br, rat brain control. 
species of PKC was not detected at any growth stage. Con-
tact-inhibiting Swiss 3T3 fibroblasts expressed a similar PKC 
subspecies profile (results not shown). As revealed in Fig. 
lA,B, Western blotting under standardised conditions with 
equal protein loadings (30 ~g) revealed that the protein con-
tent of PKC subspecies a and 0 increases as 3T6 fibroblasts 
grow from low cell density to high density in the presence of 
serum. Laser densitometry of chemiluminescence bands sug-
gests that protein expression of PKC-a increases some 2-fold 
whereas that of PKC-o increases 4--5-fold. Protein expression 
of PKC-131 (results not shown) and of PKC-I;. (Fig. lC) does 
not change significantly as 3T6 cells grow to confluency under 
the same conditions. 
3.2. Down-regulation of PKC-e protein expression in growing 
3T6 fibroblasts 
Western blotting results in Fig. 2A show that PKC-e pro-
tein is expressed in 3T6 fibroblasts growing at low cell density 
but that this expression is completely down-regulated as cells 
become more dense and exceeds 50% coverage of the plastic 
growth surface. PKC-e protein cannot be detected in 3T6 
fibroblasts at higher cell densities growing in DMEM/lO% 
FBS, even when chemiluminescence detections are overex-
posed. Swiss 3T3 cells which have lost the property of contact 
inhibition show the same complete down-regulation of PKC-e 
protein when growing to increased cell density. However, this 
seems not to be the same for true contact inhibiting Swiss 3T3 
fibroblasts where preliminary results show that PKC-e protein 
expression is decreased by about 50% but is not completely 
down-regulated as cells grow to confluency (Watson, J. and 
Rumsby, M.G., unpublished results). When confluent 3T6 
fibroblasts, not expressing PKC-e protein, are passaged with 
trypsin/EDTA (5 min) and then transfered into new flasks 
with fresh medium, expression of PKC-e protein is rapidly 
up-regulated and protein can be detected by Western blotting 
within 15 min of cells settling on the plastic substratum (Fig. 
2B). This new PKC-e protein synthesis is maintained for at 
least 60 min after passage but is down-regulated again as cells 
increase in density. No new PKC-e expression occurs during 
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Fig. 2. A: Protein expression of PKC-E (arrow head) is only detected in 3T6 cells at low (30%) cell density (lane I) and is down-regulated as 
cells grow to high density in the presence of serum. Lane 2: 50-60% density. Lane 3: 100% density. Lane 4: overgrowing. 30 Ilg cell protein 
was resolved in all cases as described. Markers are 89 and 77 kDa. B: Western blot analysis showing rapid PKC-E protein synthesis when con-
fluent 3T6 cells are trypsinised and passaged to low density in fresh medium and new flasks. Lane I, rat brain control. Lanes 2-4: trypsin 
treatment for 0,5 and 10 min at 37°C. Lanes 5-8: 3T6 cells 15, 30,45 and 60 min after settling into new flasks in DMEMIlO% FBS. Lane 9: 
peptide control. Markers are 97, 89 and 77 kDa. 
the trypsin treatment alone (Fig. 2B). This resynthesis of 
PKC-£ protein is inhibited by pre-incubating newly passaged 
cells during trypsinisation with 10 J..lM cycloheximide, an in-
hibitor of protein synthesis (Fig. 3). The PKC-£ resynthesis is 
not inhibited by pre-treatment of passaged cells with the tran-
scription inhibitor actinomycin D (Fig. 3), also at 10 J..lM 
concentration. 
3.3. Detection of PKC-£ mRNA by RT-PCR 
Results in Fig. 4A show that amplified cDNA fragments 
produced using the appropriate primers for PKC-i) and 
PKC-£ have the predicted sizes of 359 and 506 bp, respectively 
[13]. The amplified cDNA bands cut with the predicted spe-
cific restriction endonuclease, namely HindIII for PKC-i) and 
BstXI for PKC-£, providing further confirmation of identity 
(results not shown). The nature of the PKC-£ amplified band 
was further confirmed when Southern blots were probed with 
a 32P-Iabelled DNA fragment corresponding to the V3 region 
of PKC-£ (Fig. 4B). We routinely observed an amplified 
cDNA fragment of approximately 440 bp which migrated in 
between the PKC-i) and PKC-£ amplified fragments (Fig. 4B, 
arrow): this band did not cut with the restriction enzymes 
specific for PKC-i) or PKC-£ and did not seem to hybridise 
to the probe specific for PKC-£ (Fig. 4B). The identity of this 
amplified fragment is unknown. We confirmed that equal 
amounts of total RNA were being taken for RT-PCR by 
running 3 J..lg total RNA on formaldehyde gels and noting 
that ribosomal bands had equal intensities on ethidium bro-
mide staining (results not shown). 
The results in Fig. 4A,B show that amplified cDNA frag-
ments corresponding to PKC-£ are obtained by RT-PCR from 
total RNA extracted from 3T6 cells at all stages of cell growth 
to 100% density and overgrowing. The ethidium bromide 
staining intensity (Fig. 4A) and probe-binding (Fig. 4B) of 
the PKC-£ amplified band from cells at low, medium and 
high density and overgrowing (A) varied reflecting possible 
changes in mRNA levels. Regardless of such variations, 
mRNA for PKC-£ is clearly expressed in confluent and quies-
cent cells when protein cannot be detected by Western blot-
ting methods. The amplified band for PKC-i) appears to de-
crease in ethidium bromide staining intensity in overgrowing 
3T6 cells (Fig. 4A) against the trend in PKC-i) protein expres-
sion revealed by Western blotting (see Fig. 1). With the PKC-
~ 5' and ~ 3' primers an amplified cDNA band at the expected 
size of 376 bp was detected (Fig. 5). The ethidium bromide-
stained gel of the amplified RT-PCR cDNA fragments shows 
that message levels for PKC-~ in 3T6 cells were approximately 
the same at all stages of growth to full coverage and over-
growing in agreement with the protein findings by Western 
blotting. This latter observation is also further evidence that 
equal RNA loadings are being taken for RT-PCR. 
4. Discussion 
We have previously shown [11] that the cellular content of 
PKC subspecies ex and i) increases as C6 glioma cells grow 
through several cell cycles to confluency in the presence of 
serum and enter Go. At the same time the content of PKC-y 
and PKC-£ decreases. Protein expression of PKC-~ remains 
the same throughout C6 cell growth to confluency. It is not 
yet clear in C6 cells whether these alterations in PKC subspe-
cies protein arise from changes in the regulation of mRNAI 
protein expression, or result from altered rates of protein 
turnover. The PKC subspecies protein expression patterns ob-
served in 3T6 cells growing from low to high density in this 
present work follow a similar pattern. We have now observed 
similar PKC subspecies changes in a variety of cell lines and 
in astrocytes in primary culture growing to confluency. Such 
PKC protein changes may therefore be a normal feature of 
cell growth to confluency which may be important for regu-
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Fig. 3. Effect of actinomycin D (10 )lM) and cycloheximide (10 )lM) 
on synthesis of PKC-E protein by newly passaged 3T6 fibroblasts. 
Arrow heads indicate main PKC-E bands. Lanes I and 2: 15 and 30 
min pretreatment of confluent cells with actinomycin D prior to 
passage. Lanes 3-5: 5-, 10- and 30-min pretreatment of confluent 
cells with cycloheximide prior to passage. Lane 6: Rat brain con-
trol. Lane 7: Peptide control showing elimination of PKC-E bands. 
Markers are 108, 89 and 77 kDa. 
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lating cell growth pathways, cell volume and/or cell shape as 
cells grow closer together. Over-expression of PKC-a in Swiss 
3T3 cells has been found to enhance cell growth rate, espe-
cially in low serum conditions and to reduce cell EGF recep-
tor numbers [15]: it is suggested that PKC-a may regulate 
pathways controlling EGF receptor expression. A decrease 
in EGF receptor numbers, regulated by increased PKC-a pro-
tein expression, may be important in modulating signalling 
pathways which presumably must alter as growth rates slow 
down in cells becoming more densely associated and entering 
Go. However, we show here that 3T6 cells which have lost the 
property of contact inhibition, show the same PKC-a 
changes. This suggests that PKC-a is not directly involved 
in the signalling pathways which regulate contact inhibition. 
PKC-a is clearly linked to growth control, perhaps via Raf-l 
[6], since over-expression of PKC-a in C6 glioma cells mark-
edly increases cell growth while reducing PKC-a protein with 
antisense techniques slows growth slightly (Beale, G.S. and 
Rumsby, M.G., unpublished), as is also reported for U-S7 
glioblastoma cells [16]. Overexpression of PKC-b in NIH3T3 
cells also reduced cell growth rate [S]. The protein content of 
PKC-S, reported to be of importance in mitogenic signalling 
cascades [4,5], does not change as 3T6 cells increase in density 
and enter Go. However, PKC-S activity may be regulated by a 
specific PKC-S-interacting protein, Par-4, [24] whose expres-
sion has been shown to correlate with growth inhibition and 
apoptosis [25]. Our results indicate that the cellular content of 
individual PKC subspecies change considerably at different 
stages of cell growth from low to high density. Such changes 
emphasise that the state of cell density must be controlled for 
when examining PKC subspecies protein expression. 
A notable feature of the PKC subspecies changes we have 
observed in 3T6 cells increasing in growth density is the rapid 
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Fig. 4. A: Agarose gel of RT-PCR amplified cDNA fragments 
showing expression of mRNA for PKC-E and PKC-o in 3T6 fibro-
blasts at different stages of growth density. Cells at: lane I, 30%; 
lane 2, 50%; lane 3, 70%; and lane 4, 100% (full) coverage of the 
plastic growth surface. Ethidium bromide-stained bands for PKC-E 
at the expected position of 506 bp and for PKC-o at the expected 
position of 359 bp. A minor unidentified band of 440 bp (arrow) 
was routinely observed. Marker bars are at 514, 448 and 339 bp. B: 
Identification of PKC-E mRNA (arrow) expressed in 3T6 cells at all 
stages of growth density to full coverage. Result shown was ob-
tained when the gel in A was blotted and probed with a 32P-Iabelled 
DNA fragment corresponding to the V3 region of PKC-E. Marker 
bars are at 514 bp and 339 bp. 
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Fig. 5. Detection by RT-PCR of PKC-~ mRNA in 3T6 cells at dif-
ferent stages of growth density. Ethidium bromide-stained agarose 
gel shows 376 bp amplified cDNA fragments expected for PKC-~ in 
3T6 cells at 40% coverage (lane 1), 90% coverage (lane 2) and over-
growing (lane 3). Ethidium bromide staining of the amplified bands 
is about equal indicating comparable levels of PKC-~ message at 
different stages of cell growth. Marker bars at 514, 448 and 339 bp. 
down-regulation and disappearance of PKC-E protein as cells 
become established and cover more than about 50% of the 
plastic substratum. PKC-E protein was not detected in high-
density overgrowing 3T6 fibroblasts by Western blotting, even 
when chemiluminescence development was overexposed. 
Clearly some mechanism to down-regulate PKC-E protein 
synthesis is operating well before cells make substantial con-
tacts with each other and at the same time as protein expres-
sion of the a and b PKC subspecies is increasing. This sug-
gests that pathways controlling PKC subspecies protein 
expression can be differentially regulated. These findings 
match those we noted for PKC-y and PKC-E in C6 glioma 
cells [11], where protein expression of both is down-regulated 
as cells grow to confluency. The results differ in that PKC-E 
protein in confluent C6 cells was not completely down-regu-
lated as occurs with these overgrowing 3T6 cells. We do not 
detect PKC-y protein expression in Swiss 3T6 fibroblasts. The 
fact that protein synthesis of some PKC subspecies is down-
regulated as cells grow and increase in density, while expres-
sion of other subspecies is up-regulated, further suggests that 
individual PKC subspecies are involved in the regulation of 
specific events in cells at discrete stages of cell growth. 
It seems that the Swiss 3T3 fibroblast line can lose the 
property of contact inhibition. We have found that these ab-
normal 3T3 cells have PKC-E protein changes like the 3T6 line 
cells described above. On the other hand, in preliminary ana-
lyses we find that PKC-E protein expression in true contact-
inhibiting Swiss 3T3 cells follows a pattern like that observed 
in C6 glioma cells on growth to confluency and quiescence 
[11], namely, that PKC-E protein content decreases by about 
50% but is not fully down-regulated. This perhaps represents 
an interesting difference important in the regulation of contact 
inhibition, the complete loss of PKC-E protein allowing cells 
to overgrow. 
The rapid resynthesis of PKC-E protein which occurs when 
high-density 3T6 cells are passaged is not stimulated by the 
trypsinisation process alone; subsequent transfer of released 
cells at low density in fresh medium containing serum is re-
quired to provide the signals for PKC-E resynthesis. The rapid 
resynthesis of PKC-E within 15 min of newly passaged cells 
settling on the substratum suggests that this subspecies may 
be of importance in pathways controlling cell attachment and 
cell spreading. The rapid resynthesis of PKC-E is not blocked 
by the transcription inhibitor actinomycin D indicating that it 
is not dependent on new mRNA formation. Our RT-PCR 
results show that mRNA for PKC-E is present in confluent 
cells even when protein cannot be detected. Such mRNA may 
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thus be available for rapid translation in newly passaged cells. 
PKC-£ has some of the characteristics of a novel 'early re-
sponse' protein. It is synthesised very rapidly when confluent 
3T6 cells are passaged in the presence of serum and its syn-
thesis is not dependent on transcription of new mRNA. Clas-
sical 'early response' proteins such as ornithine decarboxylase 
are under translational control [17,18], often via the 5' un-
translated region of their mRNA which has considerable sec-
ondary structure. In a 'Fold RNA' programme we note that 
PKC-£ also has a long GtC-rich 5' -UTR containing consider-
able secondary structure with two distinct loops like other 
proteins under translational control and a i1G of -125 kcalf 
mol, about the same as that of ornithine decarboxylase 
[18,19]. The 5'-UTR of ornithine decarboxylase mRNA re-
presses translation due to its stem-loop structure and removal 
of the 5'-UTR leads to normal translation [19]. mRNA for a 
number of early response proteins is present in quiescent cells 
as large messenger ribonuclear protein particles (mRNP) 
which are rapidly translated on stimulation of cells in Go 
with serum, insulin or certain growth factors [17]. We are 
looking to see if this switch also occurs for PKC-£ mRNA 
in newly passaged cells. 
The origin of the unidentified amplified fragment of 440 bp 
which we detect routinely with the PCR primers for PKCs 0 
and £ is unknown. It did not cut with the restriction endonu-
cleases used to identify the PKC-o or £ amplified fragments 
and did not hybridise conclusively with the specific PKC-£ 
probe. It has been found that PKC-£ purified from brain 
tissue migrates as two closely related bands probably differing 
in phosphorylation status [19], as is also probably the case for 
the 95 and 87 kDa forms of PKC-£ we detected in C6 cell 
extracts [11]. A smaller PKC-£-related 4.7-kb transcript as 
well as the normal 7-kb transcript for 90 kDa PKC-£ protein 
has been identified in interferon-a.-treated Daudi cells suggest-
ing that an alternative form of PKC-£ may exist [20]. 
It is not clear among the various PKC subspecies why the 
£-form should be briefly expressed in newly passaged 3T6 cells 
when other PKC subspecies, notably the a., 0 and S forms are 
continually present. Overexpression of PKC-£ in NIH3T3 
cells results in increased cell growth and higher cell density 
in monolayers [8]. PKC-£ is the only subspecies to exhibit full 
oncogenic potential, emphasising a role in growth control [8]. 
It is the only subspecies to be localised to the Golgi apparatus 
[21] and it may contribute to neoplastic transformation [8]. It 
regulates cell adhesion to the extracellular matrix [22] and, 
uniquely, it contains an actin binding motif [23]. These latter 
observations suggest that PKC-£ may be rapidly required in 
newly passaged 3T6 cells for regulating cytoskeleton assembly 
in the control of cell spreading and cell shape. The rapid 
synthesis and down-regulation of PKC-£ protein expression 
in 3T6 fibroblasts offers a convenient system in which to de-
fine the role of this specific subspecies and to study how its 
protein expression is regulated. 
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